CONTRAINDICATIONS Severe allergic reactions (e.g., anaphylaxis) to any component of CERVARIX. WARNINGS AND PRECAUTIONS Syncope Because vaccinees may develop syncope, sometimes resulting in falling with injury, observation for 15 minutes after administration is recommended. Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported following vaccination with CERVARIX. When syncope is associated […]
Cervarix, European Public Assessment Report
Authorisation details Product information Assessment history Read reports here.
Cervarix: Food and Drug Administration
Proper Name: Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant Tradename: Cervarix Manufacturer: GlaxoSmithKline Biologicals 16 October 2009, Cervarix® was approved for use in the United States, by the FDA. To examine all available FDA documents pertaining to the approval of this HPV vaccine visit the two FDA links below. Proper Name: Human Papillomavirus […]
Cervarix
Cervarix® is manufactured by GlaxoSmithKline. For information on this bivalent HPV vaccine directly from the source, visit their website here.
PRESCRIBING INFORMATION FOR CERVARIX
INDICATIONS AND USAGE CERVARIX® is indicated for the prevention of the following diseases caused by oncogenic human papillomavirus (HPV) types 16 and 18 [see Clinical Studies (14)]: Cervical cancer Cervical intraepithelial neoplasia (CIN) grade 2 or worse and adenocarcinoma in situ, and Cervical intraepithelial neoplasia (CIN) grade 1. CERVARIX is approved for use in females […]
- « Previous Page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- …
- 92
- Next Page »
